科拓生物(300858.SZ):持股6.5808%的劉曉軍擬減持不超100萬股
格隆匯2月11日丨科拓生物(300858.SZ)公佈,持有公司股份977.4542萬股(佔公司總股本比例6.5808%)的股東劉曉軍,計劃以集中競價、大宗交易的方式預計減持公司股份合計不超過100萬股,即不超過公司總股本的0.6733%。
通過證券交易所集中競價交易方式減持的,將在公司發佈減持計劃公吿之日起15個交易日後的180天內進行,且任意連續90日內減持股份總數不超過公司股份總數的1%;
通過證券交易所大宗交易方式減持的,將在公司發佈減持計劃公吿之日起3個交易日後的180天內進行,且任意連續90日內減持股份總數不超過公司股份總數的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.